Two phase I clinical trials demonstrated the safety of this molecule in patients with seropositive SLE with moderate-to-high activity [120, 121]. Post hoc analysis of the efficacy showed that the clinical effectiveness of the drug was better in patients with high initial expression of IFN gene signatures. Here, IFNA1 is linked to systemic lupus erythematosus.